Myriad’s MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestries
SALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a standard-of-care risk assessment alone. The data was shared in a spotlight discussion at the 2022 San Antonio Breast Cancer Symposium.
Working with industry-leading researchers, Myriad Genetics studied outcomes from more than 130,000 women who received RiskScore results. By analyzing data on whether women developed breast cancer after their initial test result, the study demonstrated that RiskScore was more accurate at stratifying women at high- or low-risk of developing breast cancer than a standard of care risk assessment method. Based on these findings, clinical use of RiskScore may lead to improved breast cancer prevention and screening strategies.
“This study helps to validate the performance of a polygenic risk score in a real-world setting and advance our approach to breast cancer risk assessment,” said Allison Kurian, M.D., M.Sc., Stanford University, and co-author of the study.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
RiskScore is the first breast cancer risk prediction model that combines Tyrer-Cuzick with a polygenic risk score (PRS) validated for women of all ancestries. It provides a five-year and lifetime risk assessment of developing breast cancer for women who qualify for the MyRisk Hereditary Cancer Test.
“Personalized breast cancer risk assessment depends on known traditional risk factors, specific germline mutations, and genome-wide PRS. This longitudinal patient outcomes study highlights RiskScore as a valuable precision medicine tool for predicting breast cancer risk,” said Thomas Slavin, M.D., Chief Medical Officer, Myriad Genetics. “With RiskScore, more women will be able to benefit from knowing their genomically informed risk of developing breast cancer and work with their physicians on how to best manage that risk.”
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of using RiskScore and that with RiskScore, more women will be able to benefit from knowing their genomically informed risk of developing breast cancer and work with their physicians on how to best manage that risk. These “forward-looking statements” are based on management’s expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 25, 2022, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
Source: BioSpace
